MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hiv.70249

Медицинская библиотека · HIV medicine · 2026

Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.

Qian Zheng, Liu Anni, Yang Jinjin, Qin Jiamin, Chen Wei, Ge You, Zhong Yandan, Wei Hongxia, Chen Yaling, Hu Zhiliang

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Accumulating evidence supports switching virologically suppressed people with HIV (PWH) harbouring nucleoside reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs) to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). However, real-world data on initiating B/F/TAF in individuals with NRTI RAMs and ongoing viremia remain limited.

METHODS

We retrospectively included adult PWH treated at the Second Hospital of Nanjing between June 2020 and November 2024 who had at least one NRTI RAM and an HIV-1 RNA ≥200 copies/mL at B/F/TAF initiation. The primary outcome was virological suppression at 12 months (HIV-1 RNA <50 copies/mL). Laboratory adverse events were assessed.

RESULTS

A total of 45 participants were included (97.8% male). At baseline, the median HIV-1 RNA was 36 800 copies/mL (interquartile range [IQR]: 5130-243 000), and the median CD4 cell count was 53 cells/μL (IQR: 18-307). AIDS-defining illnesses were documented in 13 participants (28.9%). M184V/I was present in 71.1% and K65R/N in 8.9%. At 12 months, 41/45 (91.1%) participants achieved HIV-1 RNA <50 copies/mL, and 44/45 (97.8%) achieved <200 copies/mL, with high suppression rates across resistance subgroups, including those with K65R/N or thymidine analogue mutations. All participants without suppression at 12 months achieved virological suppression with extended follow-up. Grade 3-4 laboratory adverse events occurred in 10/45 (22.2%) participants, most commonly severe bone marrow suppression. These events were frequently attributable to comorbidities and concomitant medications, with no discontinuations of B/F/TAF.

CONCLUSIONS

B/F/TAF demonstrated high virological suppression and acceptable laboratory safety in viremic PWH with pre-existing NRTI RAMs, supporting its use in this challenging clinical setting.

Для цитирования: Qian Zheng, Liu Anni, Yang Jinjin, Qin Jiamin, Chen Wei, Ge You, Zhong Yandan, Wei Hongxia, Chen Yaling, Hu Zhiliang. Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.. HIV medicine. 2026. DOI: 10.1111/hiv.70249.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.